REGENXBIO will participate in upcoming investor conferences. Learn more: https://lnkd.in/eVgWM7yH
REGENXBIO
Biotechnology Research
Rockville, Maryland 33,273 followers
Seeking to improve lives through the curative potential of gene therapy.
About us
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO’s AAV Therapeutic platform, including Novartis’ ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Rockville, Maryland
- Type
- Public Company
- Founded
- 2008
- Specialties
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Locations
-
Primary
Get directions
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO
Updates
-
We’re getting into the Halloween spirit at REGENXBIO! Wishing everyone a #HappyHalloween!
-
-
REGENXBIO will host a conference call on November 6th to discuss third quarter 2024 financial results and recent operational highlights. Learn more: https://lnkd.in/e_MMHb4v
-
-
At REGENXBIO, our industry-leading gene therapy Manufacturing Innovation Center enables us to accelerate product development with the goal of bringing meaningful new medicines to patients as quickly as possible. Hear from Craig Malzahn, SVP of Technical Operations, as he reflects on what sets us apart from other gene therapy companies.
-
-
Patients facing vision loss due to chronic retinal conditions are in need of new treatment options, and the annual Eyecelerator brings together leaders in ophthalmology driven to transform eye care. At this year’s meeting, Sumie Takahara, Executive Director of Global Product & Market Planning, shared how REGENXBIO is advancing potential new therapies for wet AMD and diabetic retinopathy.
-
-
We had a great day at the Children's National Hospital Race for Every Child in Washington, D.C.! REGENXBIO was proud to be a sponsor of this important event in our community, supporting Children’s National’s goal of elevating pediatric care one child at a time.
-
-
Today, we announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet AMD. Learn more: https://lnkd.in/eKASq74b #AAO24
-
-
Join REGENXBIO at the American Academy of Ophthalmology annual meeting #AAO24. Learn more about our presentations here: https://lnkd.in/d463kmqr
-
-
Our pipeline of AAV Therapeutics are in late-stage development and approaching commercialization. Hear from Sumie Takahara, Executive Director of Global Product & Market Planning, as she reflects on how we remain focused on patients as we enter our next phase as a company.
-
-
As Hispanic Heritage Month comes to a close, we are proud to spotlight another team member making her mark in #STEM. Hear from Eve Arias-LiPuma, Sr. QA Learning Specialist, about her favorite things about her culture. #HispanicHeritageMonth
-
Similar pages
Browse jobs
Stock
RGNX
NASDAQ
20 minutes delay
$8.92
0.16 (1.827%)
- Open
- 8.7
- Low
- 8.58
- High
- 8.97
Data from Refinitiv
See more info on